References
- International Coalition of Medicines Regulatory Authorities. ICMRA statement on COVID-19; [cited 2020 May 22]. Available from: http://www.icmra.info/drupal/news/statement_on_COVID-19
- World Health Organization. WHO international clinical trials platform registry; [cited 2020 May 22]. Available from: https://www.who.int/ictrp/en/
- National Institutes of Allergy and Infectious Diseases. NIAID press release; 2020 April 29 [cited 2020 May 22]. Available from: https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
- Gilead Inc. SIMPLE trial. Gilead Press Release; [cited 2020 May 22]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, multicentre, controlled trial. Lancet. 2020 [ cited 10 May 2020];395(10236):1569–1578.
- Beigel JH, Tomashek KM, Dodd L, et al. Remdesivir for the treatment of COVID-19 - A preliminary report. N Engl J Med. 2020 [ Cited 30 August 2020]. DOI:10.1056/NEJMoa2007764
- Food and Drug Administration. FDA emergency use authorization; [cited 22 May 2020]. Available from: https://www.govinfo.gov/content/pkg/FR-2017-01-13/pdf/2017-00721.pdf)
- Food and Drug Administration. FDA EUA letter of authorisation; [cited 2020 May 22]. Available from: https://www.fda.gov/media/137564/download
- Food and Drug Administration. FDA fact sheet for healthcare professionals; [cited 2020 May 22] Available from: https://www.fda.gov/media/137566/download
- Pharmaceutical Medical Devices Agency. MHLW/PMDA special approval; [cited 2020 May 22]. Available from: https://www.pmda.go.jp/english/int-activities/0004.pdf
- European Medicines Agency. European Union health threat plan; [cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/documents/other/ema-plan-emerging-health-threats_en.pdf
- European Medicines Agency. EU conditional marketing authorization; [cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation
- European Medicines Agency.EMA committee for human medicinal products compassionate use opinion on remdesivir; [cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
- European Medicines Agency. EMA committee for human medicinal products opinion summary on Veklury; [cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/veklury
- Food and Drug Administration. FDA emergency use authorization for hydroxychloroquine; [cited 2020 Aug 30]. Available from: https://www.fda.gov/media/138945/download
- Eichler HG, Cavaleri M, Enzmann H, et al. Clinical trials for Covid‐19: can we better use the short window of opportunity? Clin Pharmacol Ther. 2020 [cited 2020 Aug 30]. DOI:10.1002/cpt.1891